Subscribe To
Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology
Oral Presentation Highlighting Data on 15 Subjects from OraGrowtH212 Trial Supportive of Conclusions from Interim Data Analysis Baseline Characteristics of OraGrowtH210 Trial Subjects Highlighted in Poster Presentation AUSTIN, Texas, March 05, 2023 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase […] The post Additional Data on Lumos OraGrowtH Trials Presented at I...
Read More
Content Topics
Additional
Data
Lumos
Oragrowth
Trials
Presented
At international
Meeting
Pediatric
Endocrinology
Forex
Posted: Mar 5 2023, 19:00
Author Name: forextv
Views: 102269